Coverage
-
August 04, 2022
A proposed class of shareholders who sued a biopharmaceutical company over an unexpected delay in the approval of a breakthrough diabetes drug lost their case Thursday when a New Jersey federal judge said optimistic statements about the drug's future weren't actionable.
1 other articles on this case.
View all »